ERAS

NEUTRALProduct

Erasca, Inc.

2026-02-20

Price

$12.54

+1.21%

Score3.8Watchlist

Signals3/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

Erasca (ERAS) is executing a textbook 'High-Conviction Price Discovery' phase, structurally de-risked by its recent $258M capital raise (Jan 23) and validated by positive ERAS-0015 data. The stock's +21.9% relative strength and 'Perfect Stack' signal confirm that the market has fully absorbed the $10.00 secondary offering supply, turning previous dilution headwinds into a liquidity tailwind. Despite the 'Risk On' macro volatility, ERAS is decoupling from broad market fears, driven by idiosyncratic biotech catalysts (Patent wins, Pan-RAS narrative) rather than macro beta.

Fired Signals

SURGEGOLDEN CROSSPERFECT STACKSELLER FATIGUEEXTENSION

Key Takeaways

Structural Catalyst: The successful $10.00/share offering extends cash runway to 2027, removing financing overhang and allowing pure-play valuation of the pipeline.
Technical Confirmation: 'Seller Fatigue' on 0.5x volume implies the deal-flippers have exited; the drift higher suggests a lack of supply ahead of the $12.76 breakout level.
Event Drift: Smart money is likely positioning ahead of the Oppenheimer Healthcare Conference (Feb 25), expecting bullish commentary on the SEACRAFT-2 trials.

← Back to 2026-02-20 View Full ERAS History →Yahoo Finance &nearr;